综合一区欧美国产,99国产麻豆免费精品,九九精品黄色录像,亚洲激情青青草,久久亚洲熟妇熟,中文字幕av在线播放,国产一区二区卡,九九久久国产精品,久久精品视频免费

USEUROPEAFRICAASIA 中文雙語(yǔ)Fran?ais
China
Home / China / Society

Backlog in drug approvals reduced

By Shan Juan | China Daily | Updated: 2016-12-20 07:14

The backlog of drug registration cases in China has been substantially reduced, with 9,000 applications awaiting approval, compared with a peak of 22,000 last year, a senior official said.

"Reforms are underway to speed up the drug evaluation and registration process to improve public access to advanced treatments," said Li Jinju, deputy director of the China Food and Drug Administration's drug and cosmetics registration department.

"But safety and quality will never be compromised," Li said.

Backlog in drug approvals reduced

A shortage of staff in drug evaluation and registration is mainly to blame, she said. "That was addressed by the reforms."

There are about 10,000 applications for drug registration per year.

Before 2015, the administration's drug evaluation center had only 130 staff, including 80 specializing in drug evaluation, Li said. In comparison, a similar department in the United States has 5,000, and in Japan there are 700.

Under the reforms, "we hired more, but it takes time to build capacity and train staff as the evaluation work is highly demanding technically", she said.

The strain is expected to be substantially relieved in two to three years, she estimated.

Also, new drugs in urgent and high demand clinically will be fast-tracked for approval, she added.

So far, 146 candidates have been fast-tracked for registration and approval, including the HPV vaccine, which protects women from cervical cancer caused by HPV infection and was submitted for approval about 10 years ago.

To enhance efficiency, other reform measures like strengthened communication with drug developers and streamlined interior working procedures were introduced as well after March, she said.

In March, Bi Jingquan, head of the administration, first pledged reforms of drug registration to beef up efficiency.

He recognized that the process took longer in China and that "there was a backlog of cases".

In China, a drug candidate needs to go through applications, three phases of clinical trials, and registration and approval to become available for patients, a process that can take years.

shanjuan@chinadaily.com.cn

Editor's picks
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
台江县| 柳州市| 绿春县| 江华| 柳林县| 高邮市| 陆河县| 襄垣县| 三门峡市| 铁岭市| 淮安市| 广德县| 定日县| 醴陵市| 呈贡县| 南岸区| 江永县| 包头市| 弥勒县| 霍邱县| 渭源县| 万年县| 阿鲁科尔沁旗| 乌兰浩特市| 元氏县| 宾阳县| 高青县| 荥阳市| 梨树县| 佛冈县| 白水县| 科技| 浪卡子县| 南汇区| 金川县| 方山县| 康马县| 铜陵市| 华容县| 安国市| 兴化市|